Maybe I am wrong, but I think that Fiona Stanley has a reputation to protect.
If they undertake a publicly registered trial, they are not going to be " actively pushing with patients". What would they gain from that?
Maybe they simply didn't find enough patients that qualified for the trial criteria, within the expected, cost based, time frame.
Sure, they may still be using the product, but on an informal, ad hoc, case-by-case basis, without the additional costs of audited reporting on a predetermined, publicly listed, set of criteria.
This is all purely, IMO, and highly speculative.
- Forums
- ASX - By Stock
- Ann: Positive Patients Update - Special Access Scheme
RCE
recce pharmaceuticals ltd
Add to My Watchlist
6.15%
!
30.5¢

Maybe I am wrong, but I think that Fiona Stanley has a...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
30.5¢ |
Change
-0.020(6.15%) |
Mkt cap ! $87.95M |
Open | High | Low | Value | Volume |
32.5¢ | 33.0¢ | 30.5¢ | $54.63K | 174.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 22588 | 30.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.5¢ | 28921 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 22588 | 0.305 |
4 | 17833 | 0.300 |
2 | 10000 | 0.295 |
11 | 90433 | 0.290 |
2 | 135000 | 0.285 |
Price($) | Vol. | No. |
---|---|---|
0.315 | 28921 | 1 |
0.340 | 24538 | 1 |
0.350 | 30000 | 2 |
0.375 | 8002 | 1 |
0.380 | 6820 | 2 |
Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
Featured News
RCE (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online